TABLE 5.
Urinary excretion of finafloxacin following multiple intravenous dosesa
| Treatment group(s) | Day | Dose (mg) | Ae0–48 (mg) | fe0–48 (%) | CLR 0–48 (ml/min) |
|---|---|---|---|---|---|
| Groups 3 and 4 | 1 | 600 (n = 16) | 209 (21.2) | 34.8 (21.2) | 160 (30.0) |
| 7 | 210 (22.7) | 35.0 (22.7) | 147 (30.0) | ||
| Group 5 | 1 | 800 (n = 8) | 249 (23.1) | 31.1 (23.1) | 130 (42.0) |
| 7 | 254 (28.5) | 31.8 (28.5) | 124 (38.7) | ||
| Group 6 | 1 | 1,000 (n = 8) | 270 (25.1) | 27.0 (25.1) | 90.5 (28.8) |
| 7 | 334 (33.5) | 33.4 (33.5) | 92.2 (21.4) |
a
Data are presented as geometric means (coefficients of variation [in percent]) of the amount of drug excreted in urine from 0 to 48 h after the start of the infusion (Ae0–48), the fraction of the dose excreted in urine from 0 to 48 h after the start of the infusion (fe0–48), and renal clearance from 0 to 48 h after the start of the infusion (CLR 0–48) on days 1 and 7 in n subjects receiving multiple 1-h intravenous doses of finafloxacin (part B).